Navigation Links
FDA Permits Marketing of a System to Repair Failed, Problematic Fix for Aortic Aneurysms
Date:11/21/2011

SILVER SPRING, Md., Nov. 21, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today allowed marketing of the first system that can repair a failed or problematic aortic endograft, a fabric tube used to repair a dangerously large aortic aneurysm, a bulge in the large blood vessel that carries blood away from the heart.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

FDA's action will provide surgeons with a minimally-invasive option for repair of aortic endografts (endovascular grafts) that are not properly positioned. Aortic aneurysms can, over time, become weak and result in a life-threatening rupture. The endograft is placed inside the aorta to seal off the aneurysm and direct blood away from it.

The Aptus EndoStapling System is a cassette of nickel-cobalt corkscrew-shaped staples that is loaded into a long, thin, tube-like delivery catheter. The catheter is inserted into an artery in the leg and directed through the arteries to the failed endograft. Using a controller on the handle of the catheter, the surgeon applies one staple at a time around the top edge of the endograft to anchor the device and repair the endograft-artery seal.

"Leakage between the top end of the endograft and the aorta wall is a known complication of endograft implants that can be successfully treated," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health. "The Aptus EndoStapling System provides a less invasive option than open surgery to access and repair these leaks."

The FDA reviewed data for the Aptus EndoStapling System through the de novo reclassification process, a regulatory pathway for low- to moderate-risk medical devices that are novel and not comparable to an already legally marketed device.  

FDA granted the de novo petition for the EndoStapling System based on r
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Permits Marketing of First Test to Help Diagnose Dengue Fever
2. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
3. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
4. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
5. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
6. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
7. Infant Formula Manufacturers Again under Ethical Cloud: Marketing Gimmick Linked to Serious Illnesses
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. AMT Prepares for Submission of Marketing Authorization Dossier for AMT-011 (Glybera(R))
11. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...  Legendary actor and director Danny Glover ... designed to educate and encourage patients with neurologic conditions, ... (PBA) and to speak with their physician. The campaign ... ability to cry and laugh on cue and how ... people living with PBA episodes. While PBA ...
(Date:5/1/2015)... 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... Morris , chief financial officer  will be participating in ... as follows: Mizuho Third Annual Healthcare Corporate ... Berkshire Place, New York ...
(Date:4/30/2015)... 30, 2015 Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its first ... Revenue for the first quarter of 2015 was $116.2 ... quarter of 2014, and down $5.3 million or 4.4% ... quarter 2015 net income as reported in accordance with ...
Breaking Medicine Technology:Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27
... 2011 Telik, Inc. (Nasdaq: TELK ) reported a ... three months ended December 31, 2010, compared with a net loss ... in 2009.  For the year ended December 31, 2010, net loss ... loss of $23.7 million, or $0.44 per share, for the year ...
... Amgen (Nasdaq: AMGN ) today announced ... study of 1,776 advanced cancer patients with different types ... or multiple myeloma, which compared XGEVA ™ (denosumab) ... The study, which appeared today in the Journal ...
Cached Medicine Technology:Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 2Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 3Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 4Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 2The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 3The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 4The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 5The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 6The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 7The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma 8
(Date:5/3/2015)... 2015 Looking for a graduate ... impact your career? The Master of International Business, ... in multinational companies and for professionals seeking a ... global landscape, differences in culture, religion, government, and ... program develops the global competence and confidence needed ...
(Date:5/3/2015)... MA (PRWEB) May 03, 2015 SpineFrontier, ... clearance from the FDA to produce and market their ... device can be used in outpatient settings and is ... The alternate posterior approach has been extensively researched and ... 510k approval to use this approach in conjunction with ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company that ... the , May 5 - 7, 2015 Minnesota Safety ... the conference include its bestselling TaskMate sit stand solutions. ... 6100 TaskMate Executive. Features of the 6100 TaskMate Executive ... extended platform work surface and supply holders. Weighing 50 ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of ... awaited event today, Saturday, May 2nd at the MGM Grand ... be able to secure tickets for both the actual fight ... fans have wanted for more than five years was finally ... will step inside the ring to fight Manny “Pac-Man” Pacquiao ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ ActOn ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... to get connected with organizations to make a difference. , ... are very few things that aren’t about money, which is ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2
... is reason to believe that a gene-based treatment for heart ... of new blood vessels in hearts with severe hardening of ... thousands of patients suffering with heart disease.// ,Treatment ... surgical procedures that open blocked arteries and improve blood flow ...
... A new study from Brazil has found that coffee ... blood levels of cholesterol and the protein homocysteine.High levels ... disease. Some of the compounds, called terpenoids, are known ... Right, of Marylandl University Hospital ,US, explained that "it ...
... Children living in damp homes run greater asthma risks,say ... could double the risk of asthma, say researchers. ,A ... in damp homes not only increased the risk of ... repeated colds and skin allergies. People living in damp ...
... is an inherited blood disorder that affects red blood ... cells that contain an abnormal type of hemoglobin. Sometimes ... passing through small blood vessels. When sickle-shaped cells clump ... pain severe enough to require hospital admission. // ...
... has approved a new method to treat women suffering excessive ... the tissue at fault. Millions of women suffer menorrhagia, benign ... than 20 tampons in a single day. Thousands of women ... try hormone treatment.// ,The other option is to ...
... That's been the mantra of the media as dozens of ... clamor for the potent antibiotic. But if the supply dwindles, ... used, including a previous generation's wonder drug: penicillin. Although alternatives ... to get attention. , // ,It helped that ...
Cached Medicine News:
The opaque outer circle will white-out even the darkest iris, making your pupil the only spot of black in a sea of white....
This lens gives the appearance of mystery and mayhem behind the blackest of eyes....
Soft silicone brush tip allows atraumatic brushing and manipulation of retina surface. Silicone brush extends 3mm beyond end of cannula. Luer lock hub for easy, secure connection to a backflush handl...
Healon vitreous aspirating cannula, 21 gauge....
Medicine Products: